A new drug combination from Corcept Therapeutics, relacorilant, has shown potential in treating platinum-resistant ovarian cancer.
A phase 3 trial found that relacorilant, when combined with chemotherapy drug nab-paclitaxel, improved progression free survival compared to the chemotherapy alone, according to a March 31 news release from the drugmaker.
Patients receiving relacorilant had a 30% lower risk of disease progression, with a median progression free survival of 6.5 months compared to 5.5 months for those on chemotherapy alone.
Corcept Therapeutics plans to submit a new drug application with the FDA in the third quarter of 2025, with full trial results expected to be presented at a medical conference later this year.
